PL1874341T3 - Erytrocyty zawierające deiminazę argininową - Google Patents

Erytrocyty zawierające deiminazę argininową

Info

Publication number
PL1874341T3
PL1874341T3 PL06744562T PL06744562T PL1874341T3 PL 1874341 T3 PL1874341 T3 PL 1874341T3 PL 06744562 T PL06744562 T PL 06744562T PL 06744562 T PL06744562 T PL 06744562T PL 1874341 T3 PL1874341 T3 PL 1874341T3
Authority
PL
Poland
Prior art keywords
arginine deiminase
containing arginine
erythrocytes containing
erythrocytes
deiminase
Prior art date
Application number
PL06744562T
Other languages
English (en)
Inventor
Yann Godfrin
Pierre-Olivier Goineau
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma filed Critical Erytech Pharma
Publication of PL1874341T3 publication Critical patent/PL1874341T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06744562T 2005-04-25 2006-04-25 Erytrocyty zawierające deiminazę argininową PL1874341T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0504122A FR2884717B1 (fr) 2005-04-25 2005-04-25 Erythrocytes renfermant de l'arginine deiminase
PCT/IB2006/001004 WO2006114691A1 (en) 2005-04-25 2006-04-25 Erythrocytes containing arginine deiminase
EP06744562A EP1874341B1 (en) 2005-04-25 2006-04-25 Erythrocytes containing arginine deiminase

Publications (1)

Publication Number Publication Date
PL1874341T3 true PL1874341T3 (pl) 2009-12-31

Family

ID=35787979

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06744562T PL1874341T3 (pl) 2005-04-25 2006-04-25 Erytrocyty zawierające deiminazę argininową

Country Status (17)

Country Link
US (2) US9125876B2 (pl)
EP (1) EP1874341B1 (pl)
JP (1) JP5339899B2 (pl)
KR (1) KR101431650B1 (pl)
CN (1) CN101163497B (pl)
AT (1) ATE432711T1 (pl)
AU (1) AU2006238917C1 (pl)
CA (1) CA2606420C (pl)
CY (1) CY1109353T1 (pl)
DE (1) DE602006007122D1 (pl)
DK (1) DK1874341T3 (pl)
ES (1) ES2326549T3 (pl)
FR (1) FR2884717B1 (pl)
PL (1) PL1874341T3 (pl)
PT (1) PT1874341E (pl)
SI (1) SI1874341T1 (pl)
WO (1) WO2006114691A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US20100316620A1 (en) * 2008-02-13 2010-12-16 Vanessa Bourgeaux Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
FR2940087B1 (fr) 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9033948B2 (en) 2011-04-19 2015-05-19 Fenwel, Inc. Single collection bag blood collection system, method and apparatus
FR3005420B1 (fr) * 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
KR20240154672A (ko) 2014-02-21 2024-10-25 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3583946A1 (en) 2014-04-01 2019-12-25 Rubius Therapeutics, Inc. Enucleated hematopoietic cells comprising an exogenous antigen
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
PT3402491T (pt) 2016-01-11 2022-03-03 Rubius Therapeutics Inc Composições e métodos relacionados com sistemas celulares terapêuticos multimodais para indicações de cancro
RU2770492C2 (ru) 2016-05-03 2022-04-18 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Внутриклеточная доставка биологических молекул для индуцирования толерантности
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
US12508306B2 (en) 2018-04-25 2025-12-30 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
SG11202011078VA (en) 2018-05-09 2020-12-30 Univ Chicago Compositions and methods concerning immune tolerance
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP4149440A1 (en) 2020-05-11 2023-03-22 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
CN113750232B (zh) * 2021-09-12 2023-06-02 重庆医科大学 一种巨噬细胞膜包覆精氨酸脱亚胺酶/过氧化氢酶/ir780纳米粒、制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051382A (pl) * 1900-01-01
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPH0235081A (ja) 1988-07-26 1990-02-05 Agency Of Ind Science & Technol アルギニン・デイミナーゼおよびその用途
JPH0253490A (ja) 1988-08-16 1990-02-22 Agency Of Ind Science & Technol アルギニン・デイミナーゼ遺伝子
EP0361150B1 (de) * 1988-09-30 1994-12-14 Siemens Aktiengesellschaft Verfahren zum synchronisierten Umtasten eines Polarisationszustandes eines optischen Sendesignals eines optischen Übertragungssystems mit Überlagerungsempfang und Vorrichtung zur Durchführung des Verfahrens
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
JP3004788B2 (ja) 1991-10-28 2000-01-31 株式会社ジャパンエナジー アルギニンデイミナーゼ発現ベクター、形質転換微生物およびアルギニンデイミナーゼの製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
KR960700740A (ko) * 1993-03-23 1996-02-24 라차아드 엘 콘 세포내 생물학적 활성 물질의 캡슐화 방법 및 장치(method and apparatus for encapsulation of biologic ally-active substances in cells)
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
KR100406268B1 (ko) 1999-12-24 2003-11-19 주식회사 안지오랩 아르기닌 디이미네이즈를 유효성분으로 하는 혈관신생에 의한 질환 치료용 조성물
AU2001275810A1 (en) * 2000-07-27 2002-02-13 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
KR20040004449A (ko) * 2000-11-28 2004-01-13 휘닉스 파머컬러직스, 인크. 변형된 아르기닌 데이미나제
US7204980B2 (en) * 2002-11-18 2007-04-17 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
WO2005026319A2 (en) * 2003-08-06 2005-03-24 The Regents Of Teh University Of California Erythrocytic cells and method for loading solutes

Also Published As

Publication number Publication date
US9968663B2 (en) 2018-05-15
DK1874341T3 (da) 2009-08-03
ATE432711T1 (de) 2009-06-15
FR2884717B1 (fr) 2009-07-03
PT1874341E (pt) 2009-07-21
CA2606420C (en) 2015-01-27
EP1874341B1 (en) 2009-06-03
US9125876B2 (en) 2015-09-08
AU2006238917A1 (en) 2006-11-02
KR20080000678A (ko) 2008-01-02
CA2606420A1 (en) 2006-11-02
US20160030532A1 (en) 2016-02-04
AU2006238917C1 (en) 2011-08-04
SI1874341T1 (sl) 2009-08-31
FR2884717A1 (fr) 2006-10-27
CN101163497A (zh) 2008-04-16
ES2326549T3 (es) 2009-10-14
CN101163497B (zh) 2012-12-19
EP1874341A1 (en) 2008-01-09
DE602006007122D1 (de) 2009-07-16
AU2006238917B2 (en) 2011-04-07
JP2008538761A (ja) 2008-11-06
HK1112187A1 (en) 2008-08-29
WO2006114691A1 (en) 2006-11-02
KR101431650B1 (ko) 2014-08-20
JP5339899B2 (ja) 2013-11-13
US20080274092A1 (en) 2008-11-06
CY1109353T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
PT1874341E (pt) Eritrócitos contendo arginina-desiminase
Forman et al. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers
Churchill et al. Ischaemic preconditioning improves proteasomal activity and increases the degradation of δPKC during reperfusion
ATE508190T1 (de) Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien
Liu et al. Therapy-induced cellular senescence: potentiating tumor elimination or driving cancer resistance and recurrence?
Wang et al. Inhibition of endoplasmic reticulum stress cooperates with SLC7A11 to promote disulfidptosis and suppress tumor growth upon glucose limitation
BRPI0508470A (pt) sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
MX2009004320A (es) Inhibidores de serina proteasa tipo tripsina, y su preparacion y uso.
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
Poloznikov et al. HIF prolyl hydroxylase inhibitors for COVID-19 treatment: pros and cons
WO2008054534A3 (en) Screening systems utilizing rtp801
Carvalho et al. Redox-related proteins in melanoma progression
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
CY1116840T1 (el) Χρηση 24-norudca
Pignataro et al. Unraveling NETs in sepsis: from cellular mechanisms to clinical relevance
EA200870434A1 (ru) Аминопроизводные андростанов и андростенов как лекарственные средства против сердечно-сосудистых нарушений
Nie et al. The role of protein disulfide isomerase inhibitors in cancer therapy
MY150745A (en) Isoserine derivatives for use as coagulation factor ixa inhibitors
CY1118302T1 (el) Λωριδα χαρτιου για τον καθορισμο των ελαχιστων ανασταλτικων συγκεντρωσεων αντιβιοτικων
ATE509958T1 (de) Gegen cathepsin s gerichtete therapie
Wang et al. Carbonic anhydrase II does not regulate nitrite‐dependent nitric oxide formation and vasodilation
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
EP2006287A4 (en) CONNECTION WITH ANTIMALARIA EFFECT AND ANTIMALARIAL MEDICAMENT CONTAINING THEM AS ACTIVE AGENTS
ATE485261T1 (de) Salicylsäurederivate